● Nvidia-Shaken, AI-Driven, Rate-Slammed, Meta-Muse Shock, Nasdaq Bloodbath

The event more important than the Nasdaq selloff: U.S. 10-year Treasury yields above 5% and Meta’s AI agent “Muse” reshaping market structure

The key issue in this market is not simply the decline in the Nasdaq.

Rising U.S. Treasury yields, Brent crude moving back above $100, the possibility of additional Federal Reserve tightening, and Meta’s AI agent “Muse” beginning to pressure the revenue models of established platform companies are the main developments to watch.

Meta Muse is drawing attention not as a basic chatbot, but as a personal AI assistant that can compare and execute consumer actions across subscriptions, travel bookings, grocery purchases, financial accounts, and insurance products.

This trend may affect not only large-cap technology stocks, but also travel platforms, gyms, media subscriptions, brokerages, insurers, and SaaS companies.

In simple terms, the issue is less about why the Nasdaq declined and more about which industries may see their monetization models disrupted by AI agents.

1. The direct driver of the Nasdaq decline: a sharp rise in U.S. 10-year Treasury yields

The primary market pressure is coming from U.S. 10-year Treasury yields.

According to the source material, the 10-year Treasury yield rose to 5.116%, the highest level in 19 years.

A move above 5% is a significant negative signal for equities, particularly for the Nasdaq and large technology companies.

Higher rates raise corporate financing costs.

They also reduce the present value of future cash flows, which lowers the valuation of growth stocks.

As a result, high-growth technology, AI, and other long-duration assets tend to face greater pressure in a rising-rate environment.

The current Nasdaq decline is therefore better understood as a valuation adjustment driven by higher Treasury yields rather than as simple profit-taking.

2. Why yields rose: oil, economic data, and Fed commentary

The yield move reflects multiple simultaneous factors.

Higher oil prices, stronger-than-expected economic data, and hawkish Federal Reserve commentary all contributed.

2-1. Brent crude moved back above $100

Brent crude rising above $100 renewed inflation concerns.

Higher oil prices increase transportation, production, and energy costs.

This raises corporate expense pressure and can feed through to consumer prices.

For the Federal Reserve, higher oil prices increase the risk of renewed inflation.

2-2. Uncertainty around U.S.-Iran negotiations

Geopolitical developments also supported oil prices.

Markets had been looking for signs of progress in U.S.-Iran talks.

However, stronger rhetoric from Iran’s president weakened expectations for a breakthrough.

Iran indicated that, if U.S. pressure continues, freedom of navigation through the Strait of Hormuz may be affected.

It also said it would not easily give up its nuclear technology rights.

The Strait of Hormuz is a critical route for global crude transportation.

Rising tensions in the region increase supply risk and can lift global oil prices.

2-3. PMI data was stronger than expected

The S&P purchasing managers’ index also came in stronger than expected.

Both manufacturing and services data exceeded forecasts, indicating faster-than-expected expansion.

In practical terms, corporate managers reported that business conditions are better than anticipated.

Stronger growth reduces the case for near-term rate cuts.

If growth is judged to be overheating, the Fed has more justification for additional tightening.

2-4. A Fed official signaled the possibility of further rate hikes

Comments from a senior Federal Reserve official also pressured markets.

He said additional rate hikes may be necessary to contain inflation.

With PMI data firm and oil prices rising, the market reacted strongly to this hawkish tone.

The result was a broad move higher in Treasury yields, weaker Nasdaq performance, and pressure on growth stocks.

3. The main market story may actually be Meta

While most large technology stocks weakened, Meta showed relative strength.

According to the source material, Meta shares rose by about 2% intraday, moving against the market.

The reason was AI agent “Muse.”

Muse is being viewed not as a chatbot, but as a consumer-facing AI agent that can perform practical tasks on behalf of users.

This distinction matters.

Traditional AI answers questions. AI agents compare, select, purchase, cancel, and execute.

4. Meta Muse’s core feature: changing consumer behavior directly

Meta Muse is attracting attention because it can handle tasks that users find inconvenient.

For example, a user could ask it to identify subscription services that are still charging monthly fees but are rarely used.

The AI agent could review transaction data and flag unnecessary subscriptions.

If the user then asks it to cancel them, Muse could help with the cancellation process.

If this behavior becomes widespread, companies that rely on consumer inertia could face pressure on revenue retention.

Consumer inertia refers to users continuing to pay because it is easier than canceling.

Many businesses have built stable recurring revenue models on this behavior.

5. The first industry at risk: subscription services

The first area that Muse may disrupt is the subscription economy.

A common example is paid media subscriptions such as The New York Times.

Consumers often subscribe with good intentions but do not read enough to justify the cost.

In the past, many kept paying because cancellation was inconvenient.

If an AI agent warns that the service is rarely used and offers to cancel it immediately, the dynamic changes.

Netflix, Disney+, Spotify, news subscriptions, productivity apps, and cloud services could all be affected.

The core of the subscription model is recurring monthly billing.

If AI agents identify unnecessary recurring charges, churn rates may rise.

6. The second area at risk: gyms and other inertia-based businesses

Goldman Sachs said Meta Muse is pressuring stocks that depend on consumer inertia.

One example cited was Planet Fitness.

Low-cost gym chains are classic inertia-based businesses.

Many people sign up with the intention to exercise regularly, but actual attendance is often low.

Still, monthly payments continue.

For such businesses, profitability improves when a large number of members remain inactive.

However, if an AI agent begins asking users whether they want to cancel unused memberships, this structure could weaken.

7. The third area at risk: travel platforms

Travel platforms may also be affected.

Meta announced integration with travel-related services such as Expedia.

While this appears to be cooperation, it may also be an early sign that travel platforms could become execution channels for AI agents.

If a user asks for the cheapest hotel and flight combination with the best schedule, the AI agent can compare multiple platforms.

In that case, Booking Holdings and Expedia may be judged more on price and conditions than on brand strength.

Over time, platforms may lose direct customer relationships and become backend suppliers to AI agents.

This could pressure commissions and margins.

8. The fourth area at risk: brokerages and financial companies

Financial companies are not exempt.

Brokerages such as Charles Schwab generate income from customer cash balances.

When customers leave cash idle in brokerage accounts, firms can invest it at higher rates while paying customers a lower return.

This spread is an important source of revenue.

With AI agents, users may ask:

“Review my idle cash and move it into a safer product offering a higher yield.”

If that becomes common, brokers may find it harder to profit from customer inattention.

Insurance is similar.

If users ask an AI agent to compare policies and switch to a lower-cost option with better coverage, the agent could facilitate policy shopping and switching.

This would reduce profits derived from information asymmetry and consumer inconvenience.

9. Amazon is blocking the system, while Expedia and Instacart are integrating

Company responses to Muse are diverging.

Amazon has reportedly blocked Meta Muse.

By contrast, Expedia and Instacart announced integration.

This distinction may become more important over time.

Companies that block AI agents are trying to preserve direct customer access.

Companies that integrate with AI agents are trying to secure a place in a new distribution channel.

Which strategy is correct will likely depend on whether AI agents become the primary consumer interface.

Shopify was also mentioned as a potential beneficiary of this shift.

If Muse is blocked by Amazon, commerce and payment platforms such as Shopify may gain relative attention as alternatives.

10. Meta’s key advantage: distribution and free token strategy

Meta’s advantage in AI agents is not only technical.

Its main strength is distribution.

Meta controls massive user bases through Facebook, Instagram, WhatsApp, and Threads.

It can place a new product in front of hundreds of millions of users quickly.

Threads’ fast initial adoption reflected this distribution power.

Meta also has strong cash flow and computing infrastructure.

The source material noted a strategy of offering 100 million tokens per week free of charge.

This could serve as a powerful incentive for rapid user adoption.

Users may try a capable AI agent for free, then continue using it after becoming accustomed to it.

11. Monetization potential: advertising, transaction fees, and Meta Pay

Meta is unlikely to focus on immediate monetization from Muse.

In the early stage, the priority may be user adoption and habit formation.

Later monetization options could include:

• Advertising inside the AI agent interface.

• Transaction fees on purchases or bookings.

• Premium subscription plans.

• Payments infrastructure through Meta Pay.

Meta Pay is particularly important.

Users may be reluctant to share payment credentials and passwords with an AI agent.

A proprietary payment system could help Meta position itself as a secure end-to-end solution.

It could also create a new source of transaction revenue.

12. The main risks: inference cost and trust

Success is not guaranteed.

The first major risk is inference cost.

As usage rises, computing costs will also increase.

Free token distribution can accelerate adoption, but it also raises Meta’s cost burden.

This could pressure operating margins and cash flow in the near term.

Investors may question whether usage growth is coming at too high a cost.

The second risk is trust.

AI agents need access to sensitive information to handle cancellations, payments, account transfers, and insurance changes.

Users may hesitate when required to share passwords, payment details, or financial account access.

The source material noted that only 8% of respondents were willing to entrust Muse with passwords.

If users do not trust the system with sensitive tasks, adoption depth may remain limited.

Long-term success will depend as much on trust as on technology.

13. SaaS companies are also facing a warning sign

Goldman Sachs said the expanding addressable market for AI agents could pressure SaaS companies.

SaaS refers to subscription-based software.

Historically, businesses and individuals opened and used multiple SaaS products directly.

As AI agents sit in front, users may no longer interact with each application individually.

They may simply ask the agent to create a report, organize customer data, or execute a campaign.

The agent would then use the relevant software in the background.

In that scenario, SaaS brand importance may decline and the AI agent may capture the customer relationship.

Over time, this could weaken pricing power and loyalty for SaaS vendors.

14. AI tool usage is already becoming part of daily consumer behavior

Evidence suggests AI agents are extending beyond the technology sector.

The CEO of General Mills recently said he is aware that 40% of consumers used AI tools for food purchases over the past month.

This suggests AI usage is expanding into everyday consumer decisions.

AI is moving beyond productivity tools and into decision support for shopping, dining, travel, subscriptions, insurance, and investing.

15. The key structural shift: customer access is moving

The most important point is that customer access is shifting.

Previously, consumers opened Amazon, Expedia, Netflix, or brokerage apps directly.

In the future, consumers may speak to an AI agent, which then compares and executes across multiple platforms.

If this becomes the norm, the most powerful companies may be those that receive the first consumer query rather than those that simply own the product.

In the search era, Google was the primary gateway.

In the mobile era, Apple and Google’s app stores became key gateways.

In the AI agent era, Meta Muse, ChatGPT, Claude, and Gemini could become new gateways.

The company that controls this gateway may capture advertising, commerce, payments, data, and fees.

16. The most important point often missing from mainstream coverage

Many headlines focus only on the Nasdaq decline and higher rates.

The more important point is that AI agents are beginning to attack hidden sources of corporate profit.

For years, companies have monetized consumer inertia, limited information, and inattention.

Recurring subscriptions, unused gym memberships, idle brokerage cash, and difficult insurance switching have supported margins.

AI agents reduce this friction.

For consumers, they are a cost-saving tool.

For businesses, they may become a margin headwind.

That is the core implication of the Muse development.

This is not simply a new Meta app.

It is a signal that AI may begin reclaiming profits that previously came from consumer convenience gaps.

17. Key checkpoints for investors

• Monitor how long U.S. 10-year Treasury yields remain above 5%.

• Watch whether Brent crude stays above $100.

• Track whether the Federal Reserve signals additional rate hikes.

• Focus on actual usage retention for Muse, not just download rankings.

• Assess whether users allow AI agents to handle payments, passwords, and financial tasks.

• Watch for margin changes at travel platforms, subscription businesses, financial firms, and SaaS companies.

• Monitor whether Meta’s AI investment costs continue to pressure operating margins.

In the short term, interest rates and oil prices are likely to drive market direction.

Over the medium to long term, the more important theme may be how AI agents reshape revenue models across industries.

18. AI agents may become the defining theme for the tech market in the second half of 2026

Based on current trends, AI agents may become a central theme for the technology market in the second half of 2026.

The chatbot era was centered on questions and answers.

The AI agent era is centered on execution and automation.

Users may increasingly ask the AI rather than opening multiple applications.

Companies should prepare for a market in which customers do not necessarily visit their apps directly.

Investors should separate AI infrastructure winners from companies that may benefit or suffer as AI agents take over the customer interface.

Meta is among the large technology companies most aggressively pushing this shift.

The trend may lose momentum if inference costs and trust issues are not resolved.

Even so, from the perspective of customer access and distribution, Muse is more than a standard app launch.

< Summary >

The direct driver of the Nasdaq decline is the sharp rise in U.S. 10-year Treasury yields.

Yields increased due to Brent crude moving back above $100, stronger PMI data, and the possibility of additional Fed tightening.

However, the more important development is Meta’s AI agent, Muse.

Muse is an execution-oriented AI that can help with subscription cancellations, travel comparisons, grocery shopping, financial transfers, and insurance changes.

This may pressure revenue models across subscription services, gyms, travel platforms, brokerages, insurers, and SaaS companies.

The key issue is that AI agents can reduce the profits companies have historically earned from consumer inertia.

Meta is pursuing this market with distribution strength, free token usage, and potential Meta Pay integration.

The main risks remain rising inference costs and trust in handling sensitive data.

[Related Articles…]

• AI Agents and the Next Phase of Global Tech Markets

• U.S. Yield Pressure and Nasdaq Volatility: Key Market Implications

*Source: [ 내일은 투자왕 – 김단테 ]

– 나스닥 폭락보다 중요한 사건

---

● AI-Biotech Boom, Nvidia Surge, Drug Discovery Revolution

The Next AI Wave on Wall Street’s Radar: Where Biotech Meets AI Infrastructure

The key issue is not simply that “AI is entering biotech.”

Antrhopic has established its first physical biotech laboratory, while OpenAI has also introduced AI tools dedicated to drug discovery. AI is moving beyond reading papers and supporting research workflows, and into real experiments and drug development processes.

This trend is also connecting with collaborations involving global pharmaceutical companies such as Novo Nordisk and Eli Lilly, a deregulatory stance at the FDA under the Trump administration, a rebound in biotech ETFs such as ARKG, and rising demand for AI infrastructure investment spanning Nvidia, memory semiconductors, and data centers.

In other words, this is not just a biotech equity story. It is a signal for a new AI cycle that should be assessed through the lens of U.S. equity outlook, semiconductor demand, data center investment, drug discovery, and biotech ETFs.

1. A New Keyword on Wall Street: AI Biotech

One of the most prominent themes currently emerging on Wall Street is AI biotech.

Where AI was previously concentrated on chatbots, search, coding, document summarization, and customer support, it is now expanding into drug discovery and life sciences research.

In particular, the fact that Anthropic and OpenAI are both positioning biotech as a next-stage growth vector is drawing market attention.

The important point, however, is not that biotech stocks should be bought immediately.

The core issue is that every new AI application requires more compute, more GPUs, more memory, and more data centers.

For that reason, this trend is relevant not only to biotech investors, but also to those focused on Nvidia, semiconductors, cloud services, and AI infrastructure.

2. The Significance of Anthropic’s First Physical AI Biolab

The most notable development is Anthropic’s reported construction of an AI biolab.

This matters because AI is no longer confined to digital research support; it is beginning to enter physical laboratory environments.

Previously, AI functioned primarily as a “brain.”

It could read papers, analyze data, generate hypotheses, and assist with experimental design.

Now, through robotic arms and automated equipment, it is evolving toward actual experimentation.

In effect, the AI scientist is gaining hands and feet.

3. The Evolution of AI Drug Discovery: From Assistant to Active Experimenter

The progression of AI in biotech is easier to understand in sequence.

• 2024: AI primarily supported literature review, data summarization, and data organization.

  Researchers used it as an assistant to summarize papers and identify meaningful patterns in data.

• 2025: Anthropic and OpenAI began launching services tailored to biotech and drug discovery, increasing AI’s direct involvement in R&D workflows.

  Claude expanded in a science-oriented direction, while OpenAI moved toward drug-discovery-specific tools such as Rosalind.

• Recent turning point: Anthropic’s physical biolab signals AI’s entry into the experimental stage.

  Cell, protein, and compound experiments are now moving beyond simulation toward validation in real laboratory settings.

This shift is similar to the transition from software-only AI to “physical AI” in autonomous driving and robotics.

In scientific research as well, AI is beginning to move into the physical world.

4. What Changes When Autonomous Labs Emerge

Anthropic’s long-term direction appears to be a fully automated autonomous laboratory.

In this model, AI and robotics can formulate hypotheses, run experiments, analyze failures, and iterate continuously without human presence in the lab at all times.

In practical terms, the laboratory keeps operating even when people are away.

If AI and robotic systems can repeat experiments 24 hours a day, 365 days a year, the pace of drug discovery could change materially.

Human researchers face time limits and fatigue, whereas automated AI labs can achieve superior efficiency in repetition and data accumulation.

If realized, this could accelerate progress in areas such as cancer treatment, rare diseases, and other hard-to-treat conditions.

5. Expansion of Collaboration Between Novo Nordisk and Anthropic

A more concrete example of this trend is the expanded collaboration between Novo Nordisk and Anthropic.

Novo Nordisk, alongside Eli Lilly, is one of the most closely watched global pharmaceutical companies in the obesity treatment market.

Its expanded collaboration with Anthropic indicates that AI is beginning to be recognized not merely as a support tool, but as a drug discovery partner.

For pharmaceutical companies, shortening development timelines, reducing clinical failure costs, and improving R&D productivity are critical priorities.

Drug development often takes years, and in many cases more than a decade, with costs reaching into the trillions of won.

If AI can accelerate candidate screening, toxicity prediction, clinical design, and data analysis, pharmaceutical profitability could improve meaningfully.

6. Why ARKG and Biotech ETFs Are Moving Again

ARK Invest’s ARKG ETF, which holds companies focused on gene innovation, biotech, and drug discovery, is one of the main thematic ETFs drawing renewed attention.

The recent rebound reflects rising expectations around AI biotech.

As noted in the source material, ARKG had been relatively weak, but investor interest improved once Anthropic and OpenAI began expanding more aggressively into biotech.

That said, investors should remain cautious when ETFs and stocks have already moved sharply.

Biotech equities can surge on news flow, but they can also fall quickly on clinical failures or regulatory setbacks.

Accordingly, both growth potential and volatility must be considered when evaluating biotech ETFs.

7. Why AI Biotech Could Reignite Semiconductor and Data Center Demand

One easily overlooked point in this theme is that as AI biotech grows, the benefits may extend beyond biotech companies to AI infrastructure providers.

Drug discovery requires large-scale data processing.

Genomic data, protein structure data, clinical data, scientific literature, experimental results, and drug response data all need to be connected.

Processing and inference across these datasets requires GPUs, high-bandwidth memory, servers, cloud services, and data centers.

In other words, growth in AI-driven drug discovery could translate into stronger semiconductor demand and data center investment.

This is also the context behind Nvidia’s repeated emphasis that new AI demand continues to emerge.

The initial demand came from large technology firms and chatbots, followed by enterprise AI, defense, finance, and manufacturing.

Now, biotech, pharmaceuticals, national research institutions, and AI laboratories are expanding the addressable market further.

8. ARK’s View on Rising Token Demand in Drug Discovery

ARK Invest has already noted in its research that token usage in AI-based drug discovery could increase dramatically.

Even at the individual level, token consumption rises quickly when ChatGPT, Claude, or Gemini are used in daily work.

For pharmaceutical companies processing large protein structures, clinical datasets, scientific papers, and experimental results, the required compute scale is far greater.

As a result, the AI biotech market could generate much larger computational demand than many expect.

For biotech companies, this can mean lower costs and faster development. For AI infrastructure companies, it creates a new class of large-scale customers.

9. FDA Deregulation and Policy Tailwinds

Another factor supporting market optimism is the policy direction in the United States.

The source notes that the Trump administration is replacing key FDA personnel with officials seen as more supportive of deregulation.

The FDA plays a central role in drug approval and clinical authorization.

If the agency accelerates approval timelines, simplifies clinical trial procedures, and supports AI-driven drug discovery more directly, that would be a clear positive for biotech companies.

The appointment of leadership focused on AI and technology within the FDA is also symbolically important.

It suggests that the U.S. government is starting to treat AI-based drug development as part of national competitiveness rather than as a purely private-sector trend.

If deregulation, faster approvals, and innovation support all advance together, the operating environment for biotech firms could become more favorable.

10. Key AI Biotech Names Mentioned in the Market

The following companies were cited in the source material and are listed here for thematic reference, not as investment recommendations.

• Twist Bioscience

  Identified as a company directly linked to Anthropic.

  It is viewed as a potential partner for validating AI-generated designs through real laboratory testing.

  It is also a meaningful holding in the ARKG ETF and may be sensitive to AI biotech sentiment.

• 10x Genomics, TXG

  A company with strengths in cell analysis, genomic analysis, and life sciences research tools.

  It attracted attention on expectations of collaboration with Anthropic’s Claude.

• Tempus AI

  A company that uses AI to analyze clinical patient data for drug discovery and precision medicine.

  It drew market attention after constructive commentary on revenue growth at a healthcare conference.

  As a business that directly combines AI and medical data, its long-term growth narrative is relatively clear.

At the same time, individual biotech stocks often experience sharp upside followed by significant corrections.

Clinical outcomes, FDA approvals, financing needs, and partnership changes can all drive substantial volatility.

11. Eli Lilly and the Oral Obesity Drug Market

Another important theme in biotech is obesity treatment.

Currently, injectable obesity drugs such as Wegovy and Mounjaro are attracting strong demand globally.

However, market expectations for oral obesity treatments are rising quickly in the United States.

Eli Lilly has indicated at healthcare conferences that the era of oral obesity drugs is approaching.

For patients reluctant to use injections, a pill-based option offers much greater accessibility.

If obesity treatments become monthly oral therapies available through pharmacies, the model could resemble recurring subscription-like revenue for pharmaceutical companies.

That is why the comparison to Netflix-style recurring revenue is often made.

This market is likely to remain a key growth driver for Eli Lilly and Novo Nordisk.

12. The Most Important Point Rarely Emphasized in Other Coverage

The most important issue is not short-term biotech stock gains, but the structural expansion of AI’s addressable market.

Many reports stop at the idea that “AI is discovering drugs” or “biotech stocks are rising.”

From an investment perspective, however, the more important issue is that AI is proving it can generate monetizable use cases across real industries.

If Anthropic or OpenAI demonstrates that AI can identify drug candidates, improve laboratory productivity, or materially reduce pharmaceutical development costs, the market framework changes.

AI then becomes more than a chatbot; it becomes a productivity platform.

Once that is established, other sectors such as finance, manufacturing, defense, logistics, energy, healthcare, and education are likely to accelerate adoption.

This could extend the AI infrastructure investment cycle.

If biotech proves economically viable, large technology firms and pharmaceutical companies may buy more GPUs, build more data centers, and sign more cloud contracts.

For that reason, this theme may be more important as a signal for the extension of the AI infrastructure and semiconductor cycle than as a pure biotech story.

13. IPO-Related Storytelling Risk in AI Companies

That said, investors should also be cautious about overly optimistic narratives.

Anthropic and OpenAI are both frequently discussed as potential future public companies.

Companies approaching an IPO often have incentives to present the most compelling growth narrative possible.

Biotech, autonomous labs, drug discovery, and rare disease treatment are all powerful themes for investors.

On a negative read, these themes may also serve as storytelling designed to raise pre-listing valuation.

In particular, Anthropic’s reported profitability metrics may appear strong on the surface, but actual economics should be assessed after accounting for model training costs, revenue sharing arrangements with major cloud partners, cloud expenses, and operating costs.

In other words, investors should distinguish between the reality that AI biotech may be promising and the possibility that companies may selectively emphasize favorable developments ahead of a public listing.

14. Key Investment Checkpoints

• First, confirm whether the theme translates into actual revenue.

  Investors should determine whether AI biotech partnerships remain at the announcement stage or lead to measurable cost savings and research outcomes.

• Second, monitor whether FDA policy changes lead to faster approvals.

  Expectations for deregulation can support share prices, but concrete procedural changes and approval outcomes matter more.

• Third, assess whether the theme drives demand for AI infrastructure companies.

  The key question is whether biotech and pharmaceutical customers increase cloud, GPU, and data center spending.

• Fourth, manage position size in individual biotech names.

  Even with strong growth potential, volatility is extreme, and concentrated exposure to one name is risky.

• Fifth, treat pre-IPO promotional news from AI companies critically.

  The stronger the headline, the more important it is to verify the underlying numbers, contracts, and cost structure.

15. One-Sentence Summary of the Theme

AI is moving from reading papers to conducting research and now entering laboratory environments.

If this transition generates measurable results, it could connect drug discovery, biotech, obesity treatment, AI infrastructure, semiconductors, and data centers into a single large investment cycle.

However, because biotech stocks carry a large gap between expectations and reality, investors should focus on industry direction and actual execution rather than chasing short-term price spikes.

< Summary >

Anthropic’s physical AI biolab marks a turning point as AI enters the drug discovery laboratory.

OpenAI and Anthropic both view biotech and drug development as a next-stage AI growth market.

Collaboration with global pharmaceutical companies such as Novo Nordisk and Eli Lilly shows that AI is becoming a research and development partner, not just a support tool.

FDA deregulation and expectations for AI-enabled drug approvals are adding policy tailwinds to the biotech sector.

More importantly, AI biotech growth could increase demand for GPUs, memory, data centers, and cloud infrastructure.

Given the high volatility of individual biotech stocks, investors should focus on actual revenue, clinical progress, regulatory developments, and AI infrastructure demand rather than short-term momentum.

[Related Articles…]

• AI Infrastructure Investment Cycle and Semiconductor Demand Outlook
• Biotech ETFs and the Changing Drug Discovery Market

*Source: [ 소수몽키 ]

– 앤트로픽, 오픈AI가 동시에 찍은 다음 AI 혁명의 수혜주는 여기? 조용히 돈 몰리는 새로운 투자처

---